Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.

<h4>Background</h4> <p>Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metf...

Full description

Bibliographic Details
Main Authors:	Johnston, R, Uthman, O, Cummins, E, Clar, C, Royle, P, Colquitt, J, Tan, B, Clegg, A, Shantikumar, S, Court, R, O'Hare, J, McGrane, D, Holt, T, Waugh, N
Format:	Journal article
Language:	English
Published:	NIHR Journals Library 2017

Similar Items

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2018-02-01)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
by: Odette S Reifsnider, et al.
Published: (2021-08-01)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
by: Victor Sokolov, et al.
Published: (2020-04-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01)

Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice
by: Natalia Marcińczyk, et al.
Published: (2023-01-01)

In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats
by: Xueru He, et al.
Published: (2023-06-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
by: Yi-Hsuan Lin, et al.
Published: (2019-11-01)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023-08-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2013-11-01)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
by: Shuyan Gu, et al.
Published: (2016-01-01)

Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
by: Christine Clar, et al.
Published: (2009-07-01)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
by: Irina Claudia Anton, et al.
Published: (2022-06-01)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
by: Jayoung Lim, et al.
Published: (2022-01-01)

The genesis of Clough's poetry
by: McGrane, P, et al.
Published: (2008)

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2010-07-01)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
by: Jaehyun Lim, et al.
Published: (2023-07-01)

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
by: N Waugh, et al.
Published: (2010-09-01)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014-01-01)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
by: Dimitrios Patoulias, et al.
Published: (2022-08-01)

Self-monitoring of blood glucose in type 2 diabetes: systematic review
by: C Clar, et al.
Published: (2010-03-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

The bipolarity of attitudes: unfolding the implications of ambivalence
by: McGrane, J
Published: (2018)

The curious case of Queensland and a middle way for senior schooling assessment
by: McGrane, J
Published: (2018)

Stevens’ forgotten crossroads: the divergent measurement traditions in the physical and psychological sciences from the mid-twentieth century
by: McGrane, J
Published: (2015)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
by: Shih-Chieh Shao, et al.
Published: (2019-09-01)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
by: Aldo Ferreira-Hermosillo, et al.
Published: (2020-02-01)

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
by: Sharma Pawana, et al.
Published: (2010-12-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)